Symbol search
date o news sym
marketwatch
10:47 Tue 4
OthrMvrs
CVS shares rise as insurer and drug store chain ups guidance
-
http://feeds.marketwatch.com/~r/marketwatch/bulletins/~3/6cJHVrGXqG4/go
CVS
Healt
Text search
date o news
marketwatch
10:47 Tue 4
OthrMvrs
CVS shares rise as insurer and drug store chain ups guidance
-
CVS
Healt
marketwatch
10:13 Wed 5
Mrkts
Lumber Liquidators stock set to selloff after profit beat expectations but sales came up short
Shares of Lumber Liquidators Holdings Inc. were indicated down about 5% in premarket trading Wednesday, after the wood flooring retailer reported first-quarter profit that beat expectations but sales that came up short, as results continued to be impacted by tariffs on certain products imported from China. Net income fell to $10.6 million, or 36 cents a share, from $12.2 million, or 42 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share came to 34 cents, above the FactSet consensus of 23 cents. Net sales rose 6.0% to $283.5 million, below the FactSet consensus of $293.1 million, as same-store sales grew 6.9% to miss expectations of a 10.4% rise. The company said same-store sales were driven by strong demand for installation and home improvement projects and shutdowns related to the COVID-19 pandemic a year ago. Cost of sales rsoe 3.4% to $167.9 million. The company did not provide financial guidance, citing uncertainties surrounding the impact of the COVID-19 pandemic as it relates to consumer spending and supply chain disruptions. The stock has dropped 19.5% year to date through Tuesday, while the S&P 500 has climbed 10.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
LL
Consu
proactiveinvestors co uk
08:43 Wed 5
Nws
Hiscox premiums rise on growth in UK and Europe
The insurer says paying valid business interruption claims as quickly as possible


@MarketCurrents
15:40 Tue 4
TrdId
$PFE $ABBV $JNJ - Shares of major drug makers in focus as House committees hold hearings on drug pricing bill https://t.co/R0tkYYWHn2
-


abc net au
21:39 Tue 4
OthrMvrs
ANZ profits from COVID rebound as Westpac sued for insider trading; ASX rises despite rate rise fears
Australian shares rise despite a tech-led sell-off on Wall Street overnight. ANZ announces a huge profit rise, whileWestpac faces an insider trading court actionfrom ASIC.


marketwatch
11:17 Wed 5
TrdId
New York Times beats earnings estimates and offer upbeat guidance
New York Times Co. shares edged slightly higher in premarket trade Wednesday, after the newspaper group beat earnings estimates for the first quarter and offered upbeat guidance for the second quarter. The company posted net income of $41.1 million, or $24 cents a share, for the quarter, up from $32.9 million, or 20 cents a share, in the year-earlier period. Adjusted per-share earnings came to 26 cents, more than double the 12 cents FactSet consensus. Revenue climbed 6.6% to $473 million from $443.6 million, also ahead of the $461.0 million FactSet consensus. 'The Times finished the first quarter with more than 7.8 million paid subscriptions across our digital and print products, more than 100 million registered users, and an average weekly audience of 76 million readers,' Chief Executive Meredith Kopit Levien said in a statement. Subscription revenue rose 15.3% to $329.1 million, ad revenue fell 8.5% to $97.1 million and other revenue fell 10% to $46.8 million. Revenue from digital-only products rose 38.1% to $179.6 million. The company is expected total subscription revenue to rise about 15% in the second quarter and for digital-only subscription revenue to rise about 30%. Ad revenue is expected to grow 55% to 60%, while digital ad revenue is expected to climb 70% to 75%, boosted by weak comparisons in the first quarter of 2020 as the pandemic began to hurt ad spending. Shares have fallen 13% in the year to date, while the S&P 500 has gained 10.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


economictimes indiatimes
4h ago
OthrMvrs
MRF shares rise 0.23% as Sensex slides
A total of 394 shares changed hands on the counter till 11:23AM (IST)


economictimes indiatimes
05:47 Tue 4
OthrMvrs
IGL shares rise 0.77% as Sensex climbs
A total of 24,297 shares changed hands on the counter till 11:17AM (IST)


economictimes indiatimes
05:01 Mon 3
OthrMvrs
PI Industries shares rise 0.85% as Sensex slides
A total of 1,205 shares changed hands on the counter till 10:31AM (IST)


economictimes indiatimes
05:58 Mon 3
OthrMvrs
Indus Towers shares rise 0.71% as Sensex slides
A total of 38,514 shares changed hands on the counter till 11:28AM (IST)


economictimes indiatimes
07:47 Mon 3
OthrMvrs
Havells India shares rise 0.08% as Sensex slides
A total of 38,025 shares changed hands on the counter till 01:17PM (IST)


economictimes indiatimes
05:37 Tue 4
OthrMvrs
Indian Oil Corp. shares rise 1.26% as Sensex climbs
A total of 717,851 shares changed hands on the counter till 11:07AM (IST)


economictimes indiatimes
06:44 Tue 4
OthrMvrs
Colgate-Palmolive shares rise 1.03% as Sensex climbs
A total of 8,914 shares changed hands on the counter till 12:14PM (IST)
CL
Consu
cnbc
08:55 Wed 5
OthrMvrs
Australian shares rise almost 0.4% as Hong Kong and Singapore shares struggle for gains
The benchmark ASX 200 advanced 0.39% to 7,095.80 with the heavily-weighted financials subindex rising 0.57%


@MarketCurrents
14:31 Mon 3
OthrMvrs
$EL - Estee Lauder shares down on mixed FQ3 results and soft guidance https://t.co/Pd9GqdAgfe
-
EL
Consu
fool
18:06 Tue 4
OthrMvrs
Why Gartner's Shares Popped 20.9% Today
The earnings beat was big, but guidance should get investors' attention.


marketwatch
11:01 Tue 4
TrdId
Pfizer beats earnings expectations and lifts guidance, as COVID-19 revenue outlook increases 73%
Shares of Pfizer Inc. jumped 1.6% toward a near five-month high in premarket trading Tuesday, after the drug giant beat earnings expectations and raised its full-year outlook, as revenue expectations for its COVID-19 vaccine jumped 73%. Net income rose to $4.88 billion, or 86 cents a share, from $3.36 billion, or 60 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share increased to 93 cents from 63 cents, and beat the FactSet consensus of 77 cents. Revenue grew 45% to $14.58 billion, above the FactSet consensus of $13.54 billion. Vaccine revenue tripled, to $4.89 billion from $1.61 billion, while oncology revenue rose 18% to $2.86 billion and internal medicine revenue grew 11% to $2.59 billion. For 2021, the company raised its guidance ranges for adjusted EPS to $3.55 to $3.65 from $3.10 to $3.20 and for revenue to $70.5 billion to $72.5 billion from $59.4 billion to $61.4 billion, as revenue expectations for the COVID-19 vaccine (BNT162b2) increased to $26 billion from $15 billion. The revenue projection for BNT162b2 includes guidance for 1.6 billion doses expected to be delivered this year. The stock, which is on track to open at the highest prices seen since mid-December, has gained 8.2% year to date through Monday, while the S&P 500 has advanced 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


@MarketCurrents
14:18 Wed 5
OthrMvrs
$VECO - Veeco Instruments shares slide after soft quarterly guidance https://t.co/yge6S1XGLn
-
VECO
Techn
marketwatch
11:21 Tue 4
TrdId
Under Armour now guiding for full-year earnings rather than a loss
Under Armour Inc. stock rose 2.8% in Tuesday premarket trading after the athletic company reported first-quarter earnings that beat expectations and raised its guidance. Net income totaled $77.8 million, or 17 cents per share, after a loss of $589.7 million, or $1.30 per share, last year. Adjusted EPS of 16 cents beat the FactSet consensus for 4 cents. Revenue of $1.257 billion was up from $930.2 million and also ahead of the FactSet consensus for $1.131 billion. Under Armour now expects full-year 2021 revenue to be up at a high-teen percentage rate compared to previous guidance for a rise in the high-single-digit percentage rate. Full-year 2021 EPS is expected to be 2 cents to 4 cents, compared with previous guidance for a loss of 18 cents to 20 cents. And adjusted EPS is expected to be 28 cents to 30 cents versus previous guidance for 12 cents to 14 cents. The FactSet consensus is for revenue of $4.941 billion, suggesting a rise of 10.4% and EPS of 21 cents. Under Armour announced Monday that it has agreed to pay $9 million to settle an SEC charge that it misled investors. Under Armour neither admitted or denied the charge. Under Armour stock has gained 40.8% for the year to date while the S&P 500 index is up 11.6% for the period. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


@business
18:34 Tue 4
OthrMvrs
AMC shares fell for a sixth day as the movie chain pushed back its annual meeting at the last minute https://t.co/r1BdnkoUqu
-


forbes
13:54 Mon 3
Exploring The Role Of Supply Chain In Recovery And Digital Transformation Investments
The global semiconductor shortage has help to raise awareness of the importance of the supply chain. With much to learn from the shortage, we explore what happened, and what companies should be thinking about to get out in front of future supply chain challenges and execute on growth opportunities.


@barronsonline
21:27 Wed 5
Nws
Shares of software firm Fastly are down by double digits on disappointing guidance. Chief Financial Officer Andriel https://t.co/cdJmhnPZQx
-
FSLY
Techn
cnbc
9h ago
Nws
Circle K launches beverage subscription program for $5.99 per month
Convenience store chain Circle K is launching a beverage subscription program, following in the footsteps of Burger King and Panera Bread.


marketwatch
11:06 Tue 4
Nws
Arconic shares jump 2% premarket as earnings beat, company raises guidance
Arconic Inc. shares rose 2% in premarket trade Tuesday, after the company posted better-than-expected first-quarter earnings and raised guidance, citing higher aluminum prices and strong orders from the aerospace sector. The maker of aluminum panels for cars and planes said it had net income of $52 million, or 46 cents a share, in the quarter, up from $46 million, or 42 cents a share, in the year-earlier period. Sales rose to $1.675 billion from $1.611 billion a year ago. The FactSet consensus was for EPS of 30 cents and sales of $1.535 billion. 'We captured growth in international packaging due to better than expected regional strength and industrial end markets improved as the trade litigation came to a final positive ruling at the end of March,' Chief Executive Tim Myers said in a statement. 'Ground transportation sales also grew, largely driven by commercial transportation, but were constrained by weather impacts and the semiconductor shortage.' Arconic secured long-term contracts equal to more than $2 billion in aerospace revenue and negotiated agreements for about $1.5 billion in North American packaging revenue from 2022 to 2024, he said. It also completed a $1 billion U.S. pension partial annuitization and authorized a share buyback program of up to $300 million. The company also raised its guidance and now expects full-year revenue to range from $7.1 billion to $7.4 billion, up from prior guidance of $6.6 billion to $6.9 billion. The FactSet consensus is for sales of $6.6 billion. Shares have fallen 1.5% in the year to date, while the S&P 500 has gained 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
ARNC
Indus
marketwatch
18:40 Tue 4
TrdId
Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates
Shares of Cocrystal Pharma Inc. more than doubled on massive record volume in afternoon trading Tuesday, a day after the biotechnology company said it has made 'progress' in developing antiviral drug candidates that target coronaviruses, including those that cause COVID-19. Trading volume skyrocketed to 559.5 million shares, compared with the full-day average of about 832,300 shares. Cocrystal launched its COVID-19 program in March 2020. The stock's previous record for trading volume was 81.1 million shares on Feb. 24, 2020. 'We are aggressively developing novel coronavirus protease inhibitors for COVID-19 prophylactic and therapeutic use,' said President Sam Lee, in Monday release. 'Our high-resolution x-ray cocrystal structures further confirmed the specific covalent interaction with this conserved region of the proteases of the coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV viruses.' The stock, which was recently up 104.0%, has now run up 86.0% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 1.2% and the S&P 500 has gained 10.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
COCP
Healt
prnewswire:443
10:00 Wed 5
Nws
New Guidance on Preventing Runway Excursions Released by FSF, Partners
BRUSSELS, May 5, 2021 /PRNewswire/ -- Flight Safety Foundation today released new guidance and industry best practices aimed at preventing runway excursions the most frequent type of aviation accident and a continuing risk for large and small aircraft. The guidance, best practices and...


marketwatch
12:11 Wed 5
Nws
: Pfizers next play: A vaccine maker and pandemic partner to governments
Pfizer Inc.s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug makers top-selling drug and forging a new path into infectious diseases for the legacy drug maker.


abc net au
21:39 Tue 4
TrdId
ANZ profits from rapid COVID rebound, but tech stocks slump on rate rise fears; ASX flat
Australian shares are trading flat after a global tech sell-off overnighton concerns that interest rates may have to rise sooner than expected, but ANZ is the latest bank to profit from the fast COVID rebound.


marketwatch
11:22 Tue 4
NwsGlbl
Lilly to donate experimental COVID-19 treatment Olumiant to India
Shares of Eli Lilly & Co. gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug that is being tested as a COVID-19 treatment for the severely ill in the U.S., to the Indian government. Lilly also said it will provide royalty-free licensing agreements to drug makers there to begin manufacturing the drug. Indian regulators on Monday authorized Olumiant as a treatment for severely ill COVID-19 patients as India's COVID-19 crisis continues to worsen. Lilly's stock is up 10.1% for the year, while the broader S&P 500 has gained 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
LLY
Healt
@MarketCurrents
12:58 Tue 4
OthrMvrs
$AUD - Audacy shares rise on Genomind partnership https://t.co/QugItSnMEg
-